# Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

> **NCT01343355** · PHASE2,PHASE3 · UNKNOWN · sponsor: **St. Marianna University School of Medicine** · enrollment: 15 (estimated)

## Conditions studied

- HTLV-I-Associated Myelopathy

## Interventions

- **DRUG:** Tamibarotene

## Key facts

- **NCT ID:** NCT01343355
- **Lead sponsor:** St. Marianna University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-01
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2011-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01343355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01343355, "Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01343355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*